Group 1: Shuoshi Biotech - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year [1] - The company’s non-recurring net profit was -28.05 million yuan, a staggering decrease of 1219.78% year-on-year [1] - Eight senior executives voluntarily reduced their salaries by 5% to 50% to demonstrate solidarity during challenging times, indicating a need for innovation and market expansion to find new profit growth points [1] Group 2: BeiGene - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3: Shenzhou Cell - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% [3] - The second quarter saw a revenue of 452 million yuan, a decline of 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% [3] - Despite the revenue and profit decline, the company is actively advancing its R&D pipeline and exploring international markets [3] Group 4: Sali Medical - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company’s revenue and gross profit declined due to the transfer of some subsidiaries and challenges in its transformation, compounded by slow accounts receivable collection and difficulties in business renewals [4] - The company needs to accelerate its transformation efforts to improve performance [4]

Group 1 - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year, and a non-recurring net profit of -28.05 million yuan, down 1219.78% year-on-year [1] - Eight senior executives, including the honorary chairman and the chairman, voluntarily reduced their salaries by 5% to 50%, demonstrating a commitment to overcoming current challenges [1] - The company faces pressure from industry-wide price reductions and tax rate adjustments, leading to a decline in gross margin, necessitating a focus on innovation and market expansion for future growth [1] Group 2 - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3 - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% year-on-year [3] - The second quarter saw a revenue of 452 million yuan, down 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% year-on-year [3] - Despite the revenue decline, the company is actively advancing its R&D pipeline and exploring international markets, indicating potential for future growth [3] Group 4 - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company experienced a significant increase in net loss compared to the previous year, where the net loss was approximately 477,000 yuan [4] - Challenges include slow accounts receivable collection and difficulties in business renewals, necessitating a faster transformation to improve performance [4]

Major Events - Sihuan Pharmaceutical Holdings Group Ltd. successfully administered the first human dose of the new radiopharmaceutical conjugate drug 3D1015 [1] - Shenzhen International's joint venture Shenzhen Airlines plans to raise a total of 16 billion yuan in a phased capital increase [1] - Kangzheng Pharmaceutical received clinical trial approval for its innovative oral small molecule JAK1 inhibitor Povorcitinib for indications of vitiligo and suppurative hidradenitis [1] - Ruihe Digital signed a framework agreement with Tielin Superlight Technology to jointly advance the business of real-world asset tokenization [1] - Zhongxu Future will operate and launch a new mobile game "Miracle MU" titled "New Moon Continent" [1] Financial Performance - Noah Holdings reported a net profit attributable to shareholders of 179 million yuan for Q2, a year-on-year increase of 79% driven by strong growth in investment product distribution [1] - Trip.com Group reported a net profit of 4.846 billion yuan for Q2, an increase of 26.43% year-on-year [1] - Shijiazhuang Pharmaceutical Group announced a mid-year profit attributable to equity holders of approximately 283.5 million HKD, a year-on-year decrease of about 58.7% [1] - Zhongsheng Holdings reported a mid-year profit attributable to shareholders of 1.011 billion yuan, a decrease of 36% year-on-year [1] - SF Express City reported an adjusted net profit of approximately 160 million yuan, a year-on-year increase of 139% [1] - Baidu's subsidiary reported a mid-year profit attributable to shareholders of 47.999 million yuan, returning to profitability [1] - Li Auto reported a net profit of 1.093 billion yuan for Q2, a decrease of 0.91% year-on-year [1] - Shanghai Industrial Holdings reported a mid-year profit attributable to shareholders of 1.042 billion HKD, with an interim dividend of 0.42 HKD per share [1] - Beijing Holdings reported a mid-year profit attributable to shareholders of 3.404 billion yuan, an increase of 8.07% year-on-year [1] - Qingdao Port reported a net profit of 2.842 billion yuan, a year-on-year increase of 7.58% [1] - New China Life Insurance reported a net profit of 14.799 billion yuan, a year-on-year increase of 33.5% [1] - China Galaxy Securities reported a net profit of 6.488 billion yuan, a year-on-year increase of 47.86% [1] - China Taiping reported a 12.2% increase in shareholder profit, with a nearly 23% high growth in life insurance new business value [1] - China Resources Gas reported a mid-year profit attributable to shareholders of 2.403 billion HKD, a year-on-year decrease of 30.5% [1] - SF Holding reported a net profit of 5.738 billion yuan, a year-on-year increase of 19.37%, with volume growth exceeding the overall express delivery industry [1] - SMIC reported a net profit of approximately 320 million USD, a year-on-year increase of 35.6% [1] - SenseTime reported a revenue growth of 35.6% year-on-year, reaching 2.358 billion yuan [1] - BeiGene reported a net profit of 95.59 million USD, returning to profitability [1] - Fubo Group reported a mid-year net profit exceeding 100 million, driven by AI [1] - CITIC Securities reported a net profit of 13.719 billion yuan, a year-on-year increase of 29.79% [1] - Huadian International Power reported a net profit of 3.904 billion yuan, a year-on-year increase of 13.15% [1] Additional Financial Performance - Zhou Hei Ya reported a mid-year profit attributable to shareholders of 108 million yuan, a year-on-year increase of 228% [2] - Haitian Flavoring reported a net profit of 3.91 billion yuan, a year-on-year increase of 13.3% [2] - Dasheng Holdings reported a mid-year adjusted net profit growth of 79.6% driven by store expansion and membership growth [2] - CITIC Securities reported a net profit of 4.509 billion yuan, a year-on-year increase of 57.77% [2] - Huitongda reported a mid-year profit attributable to shareholders of 13.9 million yuan, a year-on-year increase of 10.81% [2] - Yunfeng Financial reported a mid-year profit attributable to shareholders of 486 million HKD, a year-on-year increase of 142.04% [2] - Jiufang Zhitu reported a mid-year profit attributable to shareholders of 865 million yuan, returning to profitability [2] - Air China reported a net loss of approximately 1.806 billion yuan, a year-on-year narrowing of 35.11% [2] - ZTE reported a net profit of approximately 5.058 billion yuan, a year-on-year decrease of 11.77% [2] - China Merchants Securities reported a net profit of 5.186 billion yuan, a year-on-year increase of 9.23% [2] - Datang Power reported a net profit of approximately 4.874 billion yuan, a year-on-year increase of 50.3% [2] - China Pacific Insurance reported a net profit of 27.885 billion yuan, a year-on-year increase of 11% [2] - Beijing Capital International Airport reported a post-tax loss of 164 million yuan, a year-on-year narrowing of 56.48% [2] - Dongguan Rural Commercial Bank reported a mid-year net profit of 2.629 billion yuan [2] - Shenzhen Holdings reported a mid-year loss attributable to shareholders of 2.618 billion HKD, a year-on-year increase of 137.76% [2] - China Southern Airlines reported a net loss of 1.534 billion yuan, a year-on-year increase of 45.54% [2] - COSCO Shipping Holdings reported a profit attributable to shareholders of 17.528 billion yuan, a year-on-year increase of 3.9% [2] - Guofu Hydrogen Energy reported revenue of 10.9 million yuan, actively expanding overseas cooperation and business layout [2] - Kangsheng Global reported a mid-year gross profit of 197 million yuan, with stable progress across all businesses [2] - Dongfang Electric reported a net profit of 1.91 billion yuan, a year-on-year increase of 12.91%, maintaining the industry's leading market share in nuclear and gas power [2] - Eagle Eye Technology reported a profit of 443,000 yuan, returning to profitability [2] - Haier Smart Home reported a profit attributable to shareholders of 12.033 billion yuan, a year-on-year increase of 15.6% [2] - EDA Group Holdings reached a partnership agreement with UTCPAY to collaborate in digital asset trading, Web3 technology, and blockchain applications [2] - Gilead Sciences reported that ASC30 oral tablets showed good and differentiated pharmacokinetic characteristics in the U.S. Phase Ib multi-dose escalation study [2]

Financial Performance - Total revenue reached $2.433 billion, a year-on-year increase of 44.7%, with product revenue at $2.411 billion, also up 44.5% [1][2] - The company achieved a net profit of $95.6 million, a significant turnaround from a net loss of $372 million in the same period last year [1] - Cash and cash equivalents stood at $2.756 billion, an increase of $129 million from the beginning of the year [1] - Gross margin improved from 84.3% in the previous year to 86.4% [1] Core Business Progress - Baiyueze continued to lead with revenue of $1.742 billion, accounting for 72% of product revenue, and a year-on-year growth of 54.7% [1][4] - The U.S. market showed strong performance with revenue of $1.249 billion, a 50.1% increase, surpassing the Chinese market for the first time [1][4] - Collaboration revenue from Amgen increased significantly to $14.55 million, compared to $840,000 in the previous year [1] - Operating expenses grew by 12.2% to $2.004 billion, significantly lower than the revenue growth rate [1] Development Strategy - The company deepened its global layout by relocating its registered office to Switzerland and adopting the new name "BeOne Medicines Ltd." [1][5] - Capital commitments for capacity construction reached $62 million, with ongoing investments in infrastructure [1][5] - R&D expenses amounted to $1.007 billion, representing 41.4% of total revenue, with a year-on-year increase of 10% [1] - The company anticipates over 20 R&D milestone events in the next 18 months [1][5] Future Focus Areas - Sustainability of growth in the U.S. market and risks associated with reliance on a single product [1][8] - Progress in establishing a second growth curve and the commercialization timeline for new products [1][8] - Challenges in cost control due to the complexities of global operations [1][5][8] - The impact of stock incentive expenses amounting to $246 million on actual cash generation capabilities [1][3][8]

Performance Summary - SF Holding reported a revenue of 146.858 billion yuan, a year-on-year increase of 9.26%, and a net profit of 5.738 billion yuan, up 19.37% year-on-year [2] - Shanghai Pharmaceuticals achieved a revenue of 141.593 billion yuan, a growth of 1.56%, with a net profit of 4.459 billion yuan, increasing by 51.56% [2] - New China Life Insurance's revenue reached 69.429 billion yuan, a 25.5% increase, and a net profit of 14.799 billion yuan, up 33.5% [2] - Huadian International Power's revenue was 59.953 billion yuan, down 8.98%, while net profit increased by 13.15% to 3.904 billion yuan [2] - China Pacific Insurance reported a revenue of 55.964 billion yuan, a slight increase of 0.2%, and a net profit of 6.764 billion yuan, up 12.2% [2] - CITIC Securities had a revenue of 46.552 billion yuan, a 16.28% increase, and a net profit of 13.719 billion yuan, up 29.79% [2] - Beijing Enterprises Holdings reported a revenue of 44.529 billion yuan, a 5.2% increase, and a net profit of 3.404 billion yuan, up 8.1% [2] - Li Auto's vehicle sales revenue for Q2 2025 was 28.9 billion yuan, down 4.7%, with a net profit of 1.093 billion yuan, a decrease of 0.9% [2] - Huishang Bank reported a revenue of 21.157 billion yuan, a 2.25% increase, and a net profit of 9.109 billion yuan, up 5.55% [2] - SMIC achieved a revenue of 4.456 billion USD, a 22% increase, with a net profit of 320 million USD, up 35.6% [2] - China Galaxy Securities reported a total revenue of 18.798 billion yuan, an 18.92% increase, and a net profit of 6.488 billion yuan, up 47.86% [2] - Zhongjun Group Holdings had a revenue of 18.521 billion yuan, down 25.4%, with a net loss of 3.48 billion yuan, a narrowing of 5.5% [2] - BeiGene reported a revenue of 2.433 billion USD, a 44.7% increase, and a net profit of 95.59 million USD, turning from a loss of 372 million USD [2] - SF Express City reported a revenue of 10.236 billion yuan, up 48.8%, and a net profit of 137 million yuan, up 120.4% [2] - China Shipbuilding Defense reported a revenue of 10.173 billion yuan, a 16.54% increase, and a net profit of 526 million yuan, up 258.46% [2] - Qingdao Port reported a revenue of 9.434 billion yuan, a 4.04% increase, and a net profit of 2.842 billion yuan, up 7.58% [2] - Shanghai Industrial Holdings reported a revenue of 9.476 billion yuan, down 8.6%, and a net profit of 1.042 billion yuan, down 13.2% [2] - Everbright Securities reported a revenue of 7.481 billion yuan, a 17.7% increase, and a net profit of 1.683 billion yuan, up 21% [2] - Baozun reported a revenue of 4.617 billion yuan, a 5.63% increase, with a net loss of 97.04 million yuan, narrowing [2] - Sichuan Chengyu Expressway reported a revenue of 4.08 billion yuan, down 23.3%, and a net profit of 838 million yuan, up 20.1% [2] - Baideli Holdings reported a revenue of approximately 3.813 billion yuan, down 10.9%, and a net profit of 7.1 million yuan, down 79.1% [2] - Tigermed reported a revenue of 3.25 billion yuan, down 3.21%, and a net profit of 383 million yuan, down 22.22% [2] - Zhengli New Energy reported a revenue of 3.172 billion yuan, a 71.9% increase, and a net profit of 220 million yuan, turning from a loss of 130 million yuan [2] - Sensong International reported a revenue of 2.687 billion yuan, down 22.7%, and a net profit of 338 million yuan, down 10.15% [2] - Dasheng Holdings reported a revenue of approximately 2.593 billion yuan, a 27% increase, and a net profit of 65.924 million yuan, up 504.4% [2] - SenseTime reported a revenue of 2.358 billion yuan, a 35.6% increase, with a gross profit of 908 million yuan, up 18.4%, and an adjusted net loss of 1.162 billion yuan, narrowing by 50% [2] - Ruian Real Estate reported a revenue of 2.074 billion yuan, flat year-on-year, with a net profit of 51 million yuan, down 29.2% [2] - Shangri-La Asia reported a revenue of 1.056 billion USD, a 0.7% increase, and a net profit of 57.9 million USD, down 38.7% [2] - Quanfeng Holdings reported a revenue of 912 million USD, an 11.9% increase, and a net profit of 95.217 million USD, up 54.8% [2] - COSCO Shipping Ports reported a revenue of 806 million USD, a 13.6% increase, and a net profit of approximately 182 million USD, up 30.6% [2] - Tianjin Development reported a revenue of 1.719 billion yuan, down 5.59%, and a net profit of 344 million yuan, up 19.57% [2] Company News - Sillodic Pharmaceuticals successfully administered the new radiolabeled drug 3D1015 to patients with PSMA-positive metastatic castration-resistant prostate cancer, demonstrating safety and preliminary efficacy [2] - Shoucheng Holdings signed a strategic cooperation framework agreement with Alter and Alrite to jointly promote breakthroughs in robotics technology, scene implementation, and industrial chain collaboration [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 截至2025年6月30日止六個月 中期業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2025年6月30日止六個月（「報告期」）的未經審核簡明綜合業績連同2024 年相應期間的比較數字，其乃根據美國公認會計原則（「美國公認會計原則」或 「GAAP」）編製並由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 • 截至2025年6月30日止六個月的收入合計較截至2024年6月30日止六個月增 加約751.8百萬美元或約44.7%至約2,432.6百萬美元。產品收入較截至2024 年6月30日止六個月增加約742.5百萬美元或約44.5%至約2,410.6百萬美元。 • 截至2025年6月30日止六個月的經營費用合計較截至 ...

Group 1: Financial Performance - The company reported a total revenue increase of approximately $751.8 million or about 44.7% to approximately $2,432.6 million for the six months ending June 30, 2025 [1] - Product revenue increased by approximately $742.5 million or about 44.5% to approximately $2,410.6 million during the same period [1] - The net profit for the period was approximately $95.6 million, a significant recovery from a net loss of approximately $371.6 million for the six months ending June 30, 2024 [1] Group 2: Research and Development Expenses - Research and development expenses increased by $91.7 million (or 10.0%) from $915.1 million in the previous year to $1,006.8 million for the six months ending June 30, 2025 [1] - Internal R&D expenses grew by $21.5 million (or 3.7%) to $606.5 million, primarily due to the expansion of global R&D facilities and an increase in clinical and preclinical candidates [1] Group 3: Gross Profit and Margin - Gross profit from product sales increased to $2,081.0 million, up from $1,405.0 million in the same period last year, driven by the increase in product revenue [2] - The gross margin improved from 84.2% in the previous year to 86.3% for the six months ending June 30, 2025, attributed to a higher sales proportion of Baiyueze compared to other products [2] Group 4: Sales Performance of Baiyueze - Global sales of Baiyueze reached $1,741.5 million, a growth of 54.7% compared to the same period last year [3] - U.S. sales of Baiyueze totaled $1,246.9 million, a 50.1% increase from $830.8 million, driven by robust demand across all indications and moderate net pricing benefits [3] - European sales of Baiyueze amounted to $266.4 million, a year-on-year increase of 79.7%, benefiting from market share growth in major European markets [3]

Core Insights - The company reported a total revenue of 2.433 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 44.73% [1] - Gross profit reached 2.103 billion USD, up 48.33% compared to the previous year [1] - The net profit was 95.59 million USD, a turnaround from a net loss of 372 million USD in the same period last year, with basic earnings per share of 0.07 USD [1] Revenue Breakdown - The increase in total revenue was primarily driven by sales growth of the company's self-developed products, Baiyueze and Trelatuzumab, as well as an increase in sales from licensed products, mainly from Amgen [1] - Product revenue net increased by 44.5% to 2.4106 billion USD, compared to 1.6681 billion USD in the same period last year, largely due to significant sales growth of Baiyueze in the US and Europe [1] - Baiyueze's global sales reached 1.7415 billion USD, a 54.7% increase year-on-year, with US sales totaling 1.2469 billion USD, up 50.1% from 830.8 million USD last year [2] Market Position - Baiyueze continues to maintain a leading market share among new patients in the BTK inhibitor class, supported by robust demand across all indications and moderate gains from net pricing [2]

Group 1 - The core viewpoint of the articles highlights the significant financial performance of BeiGene, with a total revenue of 2.433 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 44.73% [1] - Gross profit reached 2.103 billion USD, an increase of 48.33% compared to the previous year [1] - The net profit for the period was 95.59 million USD, a turnaround from a net loss of 372 million USD in the same period last year, with basic earnings per share of 0.07 USD [1] Group 2 - The increase in total revenue is primarily attributed to the sales growth of the company's self-developed products, including Baiyueze® and Tislelizumab, as well as the sales of licensed products, mainly from Amgen [1] - For the six months ending June 30, 2025, product revenue net increased by 44.5% to 2.4106 billion USD, up from 1.6681 billion USD in the same period last year [1] - Baiyueze® global sales reached 1.7415 billion USD, a 54.7% increase year-on-year, with U.S. sales totaling 1.2469 billion USD, up 50.1% from 830.8 million USD in the previous year [2] Group 3 - The robust growth in Baiyueze® sales is attributed to strong demand across all indications and moderate gains from net pricing [2] - Baiyueze® continues to maintain a leading market share among new patients in the BTK inhibitor class due to its differentiated and best-in-class clinical characteristics [2]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.26% on August 28, with a trading volume of 2.227 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% per year and a custody fee of 0.10% per year [1] - As of August 27, 2024, the fund's latest share count was 6.506 billion shares, with a total size of 6.134 billion yuan, reflecting a year-to-date increase of 1545.50% in shares and 1523.46% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 88.56% during the tenure [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The fund's liquidity is strong, with a cumulative trading amount of 35.359 billion yuan over the last 20 trading days, averaging 1.768 billion yuan per day [1][2]